Tranexamic Acid in Patients With Traumatic Bleeding Based on Dynamic Monitoring of Thromboelastography
Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Dec 15, 2024
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called tranexamic acid (TXA) in patients who have experienced traumatic bleeding. The goal is to see if giving TXA in a tailored way, based on real-time monitoring of blood clotting, can help reduce the risk of death after a traumatic injury. The researchers want to compare the standard method of giving TXA (a one-time dose followed by a steady infusion) with a new approach that allows for additional doses if needed. This could potentially improve survival rates and make the treatment safer.
To be eligible for the trial, participants must be between 18 and 80 years old and have certain criteria, such as low blood pressure or a rapid heart rate due to trauma. They also need to start receiving TXA within three hours of their injury. Participants will be closely monitored during the study, and the researchers will be looking at how effective the treatment is in preventing complications from bleeding. This trial is important because it aims to improve how TXA is used in trauma cases, which could lead to better outcomes for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. . trauma patients 18 -80 years of age (50 points \> trauma ISS score \> 16);
- • 2. . hypotension (systolic blood pressure ≤ 90 mm Hg) and/or tachycardia (heart rate ≥ 110 beats/min);
- • 3. . receiving a 1 g TXA push within 3 h of the injury, with the push completed within 10 min of arrival at the hospital.
- • 4. . signing the informed consent form.
- Exclusion Criteria:
- • 1. .Coagulation abnormalities due to co-morbid hematologic or autoimmune diseases
- • 2. Inability to establish venous or intraosseous access
- • 3. Pregnant women
- • 4. Traumatic cardiac arrest for more than 5 minutes
- • 5. Failure of cardiopulmonary resuscitation
- • 6. Penetrating brain injury
- • 7. Drowning or hanging -
About Nanfang Hospital, Southern Medical University
Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported